Reg­u­la­to­ry in­tel­li­gence: Up­date on re­gen­er­a­tive med­i­cine ad­vanced ther­a­pies des­ig­na­tions

This ar­ti­cle dis­cuss­es the scope and pur­pose of the spe­cial des­ig­na­tion for Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­pies (RMAT) cre­at­ed by the pas­sage of the 21st Cen­tu­ry Cures Act. The au­thors ex­plain the ben­e­fits ex­pect­ed to be re­al­ized with RMAT, such as keep­ing the US glob­al­ly com­pet­i­tive in the field. They pro­vide a tal­ly of prod­ucts re­ceiv­ing the spe­cial des­ig­na­tion to date and a cur­rent count, by year, of prod­ucts for which RMAT des­ig­na­tion has been re­quest­ed.

In­tro­duc­tion

Sec­tion 3033 of the 21st Cen­tu­ry Cures Act, ti­tled “Ac­cel­er­at­ed Ap­proval for Re­gen­er­a­tive Ad­vanced Ther­a­pies,” cre­at­ed a spe­cial des­ig­na­tion for Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­pies (RMAT). A prod­uct is el­i­gi­ble for RMAT des­ig­na­tion if it is a re­gen­er­a­tive med­i­cine ther­a­py, such as cell ther­a­py, ther­a­peu­tic tis­sue en­gi­neer­ing prod­uct, hu­man cell and tis­sue prod­uct, gene ther­a­py or any com­bi­na­tion prod­uct us­ing such ther­a­pies or prod­ucts, and is in­tend­ed to treat, mod­i­fy, re­verse or cure a se­ri­ous or life-threat­en­ing dis­ease or con­di­tion and pre­lim­i­nary clin­i­cal ev­i­dence in­di­cates that the drug has the po­ten­tial to ad­dress un­met med­ical needs for such dis­ease or con­di­tion.

Oth­er na­tion­al bod­ies have in re­cent years made spe­cial reg­u­la­to­ry pro­vi­sions to rec­og­nize the val­ue of re­gen­er­a­tive med­i­cine prod­ucts. For ex­am­ple, Japan’s SAKI­GAKE des­ig­na­tion,  was in­tro­duced in 2015 to pro­mote R&D of re­gen­er­a­tive med­i­cines and oth­er in­no­vate phar­ma­ceu­ti­cals and med­ical de­vices.

RMAT des­ig­na­tion has helped keep the US com­pet­i­tive in the glob­al field, while ad­dress­ing spe­cif­ic needs and re­quire­ments of re­gen­er­a­tive med­i­cine ad­vanced ther­a­py prod­ucts. The ben­e­fits of an RMAT des­ig­na­tion are the same as the ben­e­fits for break­through ther­a­pies and in­clude in­ter­ac­tions with FDA to ex­pe­dite de­vel­op­ment and re­view of the prod­uct and con­sid­er­a­tion of the prod­uct for pri­or­i­ty re­view or ac­cel­er­at­ed ap­proval. Re­ceiv­ing RMAT des­ig­na­tion al­so al­lows for in­creased flex­i­bil­i­ty in clin­i­cal tri­al de­sign, for in­stance, in the num­ber of clin­i­cal tri­al sites. De­vel­op­ers al­so have the po­ten­tial to use pa­tient reg­istry da­ta and oth­er re­al-world sources in post-ap­proval path­ways.

While de­vel­op­ers seek­ing break­through des­ig­na­tion are re­quired to show that their ther­a­peu­tic can­di­date would pro­vide a sub­stan­tial im­prove­ment over ex­ist­ing ther­a­pies, RMAT des­ig­na­tion on­ly re­quires that the ther­a­py have the po­ten­tial to ad­dress un­met med­ical need.

With RMAT des­ig­na­tions avail­able for more than two years, what have we seen so far?

Table 1 pro­vides FDA’s lat­est tal­ly of RMAT des­ig­na­tions by year. On­ly 2018 rep­re­sents a full year. For 2019, the num­ber of re­quests is at a high­er rate (19 re­quests through 10 April 2019) but the num­ber grant­ed is about the same rate as for 2018 (about 1.5 re­quests grant­ed per month).

Table 1. Met­rics on RMAT Re­quests by Year1
Fis­cal Year To­tal Re­quests
Re­ceived
Grant­ed De­nied With­drawn
2017 31 11 18 2
2018 47 18 27 2
2019 19 4 8 1

So far, no RMAT-des­ig­nat­ed prod­ucts have re­ceived mar­ket­ing ap­proval and no RMAT des­ig­na­tions have been re­port­ed with­drawn or re­scind­ed.

Fig­ure 1 pro­vides met­rics on des­ig­na­tion re­quests by ther­a­peu­tic area as of Sep­tem­ber 2018. The largest cat­e­go­ry is neu­rol­o­gy, fol­lowed by on­col­o­gy. This is sur­pris­ing be­cause sci­en­tif­ic pub­li­ca­tions of re­gen­er­a­tive med­i­cines for on­col­o­gy far out­pace those for neu­rol­o­gy.2

Fig­ure 2 pro­vides met­rics on des­ig­na­tion re­quests by prod­uct type as of March 2019. The great­est num­ber of des­ig­na­tion re­quests have been for cell ther­a­py prod­ucts with al­lo­gene­ic prod­ucts out­pac­ing au­tol­o­gous prod­ucts.

Fig­ure 1. RMAT Des­ig­na­tion Re­quests by Ther­a­peu­tic Area3

Fig­ure 2. RMAT des­ig­na­tion re­quests by prod­uct type4


Table 2 pro­vides a list­ing of the pub­licly an­nounced RMAT des­ig­na­tions. Twen­ty-eight have been an­nounced so far. There have been 33 RMAT des­ig­na­tions grant­ed as of 1 April 2019,3 thus five are cur­rent­ly unan­nounced.

Table 2. List­ing of Pub­licly An­nounced RMAT Des­ig­na­tions
Prod­uct Name Spon­sor Date Award­ed De­scrip­tion
HU­MA­CYL  Hu­ma­cyte 20 March 2017 acel­lu­lar ves­sel for vas­cu­lar ac­cess in he­modial­y­sis pa­tients
RVT-802  En­zy­vant 17 April 2017 al­lo­gene­ic thymic tis­sue for Di­ge­orge Syn­drome
jCell  jCyte 2 May 2017 hu­man reti­nal prog­en­i­tor cells for re­tini­tis pig­men­tosa
Ixmy­lo­cel-T  Veri­cel 10 May 2017 au­tol­o­gous ex­pand­ed mul­ti­cel­lu­lar ther­a­py for heart fail­ure due to is­chemic di­lat­ed car­diomy­opa­thy
Strat­a­Graft Mallinck­rodt 18 Ju­ly 2017 tis­sue en­gi­neered full thick­ness re­gen­er­a­tive skin tis­sue for deep par­tial thick­ness burns
ATIR101  Kiadis 20 Sep­tem­ber 2017 cell ther­a­py for leukemia
Lenti­Glo­bin  Blue­bird 1 Oc­to­ber 2017 gene ther­a­py for sick­le cell dis­ease
AST-OP­CI  As­te­r­ias 2 Oc­to­ber 2017 cell ther­a­py for spinal cord in­jury
Mul­ti­Stem  Ather­sys 5 Oc­to­ber 2017 cell ther­a­py is­chemic stroke
JCAR017  Juno (Cel­gene) 1 No­vem­ber 2017 car-t ther­a­py for re­lapsed or re­frac­to­ry dif­fuse large b-cell lym­phoma
CE­VA101  Cel­l­va­tion (Fortress Biotech) 8 No­vem­ber 2017 cell ther­a­py for trau­mat­ic brain in­jury
MPC-150-IM 
Revas­cor
Mesoblast 21 De­cem­ber 2017 mes­enchy­mal pre­cur­sor cell ther­a­py for heart fail­ure
EB-101  Abeona 29 Jan­u­ary 2018 gene ther­a­py for re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa
CAP-1002  Capri­cor 5 Feb­ru­ary 2018 cell ther­a­py for duchenne mus­cu­lar dy­s­tro­phy
Am­nioFix  MiMedx 9 March 2018 tis­sue en­gi­neered al­lo­gene­ic mi­cronized de­hy­drat­ed hu­man am­nion/chori­on mem­brane for os­teoarthri­tis of the knee
ABO-102  Abeona 23 April 2018 gene ther­a­py for San­fil­ip­po Syn­drome type a
VM202 Vi­roMed May 2018 gene ther­a­py for painful di­a­bet­ic pe­riph­er­al neu­ropa­thy
NSR-REP1  Night­star Ther­a­peu­tics 14 June 2018 gene ther­a­py for choroi­dere­ma
CLBS14-NOR­DA  Cal­adrius Bio­sciences 19 June 2018 No-Op­tion Re­frac­to­ry Dis­abling Angi­na (NOR­DA)
VY-AADC  Voy­ager 21 June 2018 gene ther­a­py for Parkin­son’s dis­ease
Romye­lo­cel-L  Celler­ant 2 Ju­ly 2018 cell ther­a­py for pre­ven­tion of in­fec­tions dur­ing neu­trope­nia
AT132 Au­dentes Ther­a­peu­tics 21 Au­gust 2018 gene ther­a­py for X-linked my­otubu­lar my­opa­thy
Avance Ax­o­Gen 29 Oc­to­ber 2018 tis­sue en­gi­neered nerve graft for pe­riph­er­al nerve re­pair
P-BC­MA-101 Po­sei­da Ther­a­peu­tics No­vem­ber 5, 2018 gene mod­i­fied CAR-T cell ther­a­py for re­lapsed/re­frac­to­ry mul­ti­ple myelo­ma
Li­fileu­cel Io­vance Bio­ther­a­peu­tics 6 No­vem­ber 2018 adop­tive gene-mod­i­fied cell ther­a­py for metasta­t­ic melanoma
RP-L102 Rock­et Phar­ma­ceu­ti­cals 27 No­vem­ber 2018 lentivi­ral vec­tor-based gene ther­a­py for Fan­coni ane­mia
FCR001 Ta­laris Ther­a­peu­tics (Re­generex) 18 April 2019 al­lo­gene­ic cell ther­a­py for im­mune tol­er­ance in kid­ney trans­plant
ECT-001 Ex­CellThera 23 April 2019 mul­ti­ple myelo­ma, high-risk leukemia, and oth­er hema­to­log­ic ma­lig­nan­cies

In the fol­low­ing month, the Al­liance for Re­gen­er­a­tive Med­i­cine plans to launch a data­base uti­liz­ing pub­licly avail­able and com­pa­ny-pro­vid­ed in­for­ma­tion to cre­ate a pub­lic list of RMAT re­cip­i­ents, as well as oth­er ex­pe­dit­ed ap­proval des­ig­na­tions award­ed in the Unit­ed States, Eu­rope, and Japan.

Clear­ly, the RMAT des­ig­na­tion pro­gram has been very ac­tive for FDA and pop­u­lar for spon­sors. We look for­ward to see­ing the first prod­ucts ap­proved un­der this pro­gram.

Ref­er­ences

  1. Cu­mu­la­tive CBER Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py (RMAT) Des­ig­na­tion Re­quests Re­ceived by Fis­cal Year. FDA web­site. https://www.fda.gov/vac­cines-blood-bi­o­log­ics/cel­lu­lar-gene-ther­a­py-prod­ucts/cu­mu­la­tive-cber-re­gen­er­a­tive-med­i­cine-ad­vanced-ther­a­py-rmat-des­ig­na­tion-re­quests-re­ceived-fis­cal. Ac­cessed 6 May 2019.
  2. Based on PubMed search com­par­ing “re­gen­er­a­tive med­i­cine on­col­o­gy” to “re­gen­er­a­tive med­i­cine neu­rol­o­gy” or “cell gene ther­a­py neu­rol­o­gy” to “cell gene ther­a­py on­col­o­gy,” 3 May 2019.
  3. Bryan WW. “Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py (RMAT) Des­ig­na­tion.” Amer­i­can So­ci­ety of Gene and Cell Ther­a­py. Li­ai­son Meet­ing. 13 Sep­tem­ber 2018.
  4. From Wil­son Bryan pre­sen­ta­tion to the Al­liance for Re­gen­er­a­tive Med­i­cine Li­ai­son Meet­ing on 28 March 2019.

Janet Lynch Lam­bert joined the Al­liance for Re­gen­er­a­tive Med­i­cine (ARM) in 2017 as the or­ga­ni­za­tion’s first CEO. She most re­cent­ly served as the act­ing head of en­gage­ment for the All of Us Re­search Pro­gram at the Na­tion­al In­sti­tutes of Health and as head of the Out­reach Of­fice in the Of­fice of the NIH Di­rec­tor. Pri­or to join­ing NIH, she was vice pres­i­dent of gov­ern­ment re­la­tions and head of the Wash­ing­ton of­fice of Life Tech­nolo­gies.

William Si­et­se­ma is vice pres­i­dent, glob­al reg­u­la­to­ry af­fairs at Cal­adrius Bio­sciences, a com­pa­ny that fo­cus­es on in­no­v­a­tive cell ther­a­pies for dif­fi­cult-to-treat dis­eases. Pri­or to Cal­adrius, he was glob­al reg­u­la­to­ry lead at Am­gen and vice pres­i­dent, glob­al reg­u­la­to­ry con­sult­ing and sub­mis­sions at Kendle In­ter­na­tion­al/INC Re­search and ad­junct pro­fes­sor of phar­ma­ceu­ti­cal sci­ences at the Uni­ver­si­ty of Cincin­nati, Col­lege of Phar­ma­cy. He may be con­tact­ed at william@si­et­se­ma.com.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Biotech and Big Phar­ma: A blue­print for a suc­cess­ful part­ner­ship

Strategic partnerships have long been an important contributor to how drugs are discovered and developed. For decades, big pharma companies have been forming alliances with biotech innovators to increase R&D productivity, expand geographical reach and better manage late-stage commercialization costs.

Noël Brown, Managing Director and Head of Biotechnology Investment Banking, and Greg Wiederrecht, Ph.D., Managing Director in the Global Healthcare Investment Banking Group at RBC Capital Markets, are no strangers to the importance of these tie-ups. Noël has over 20 years of investment banking experience in the industry. Before moving to the banking world in 2015, Greg was the Vice President and Head of External Scientific Affairs (ESA) at Merck, where he was responsible for the scientific assessment of strategic partnership opportunities worldwide.

Peter Nell, Mammoth Biosciences CBO

UP­DAT­ED: Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

When a company gets its start in gene editing pioneer Jennifer Doudna’s lab, it’s bound to make headlines. But three years in, the fanfare still hasn’t died down for Mammoth Biosciences. Now, the Brisbane, CA-based company is cheering on its first major R&D pact.

Mammoth unveiled a nearly $700 million deal with Vertex on Tuesday morning, good for the development of in vivo gene therapies for two mystery diseases. The stars of the show are Mammoth’s ultra-small CRISPR systems, including two Cas enzymes licensed from Doudna’s lab over the past couple years, Cas14 and Casɸ.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

How Chi­na turned the ta­bles on bio­phar­ma's glob­al deal­mak­ing

Fenlai Tan still gets chills thinking about the darkest day of his life.

Three out of eight lung cancer patients who received a tyrosine kinase inhibitor developed by his company, Betta Pharma, died in the span of a month. Tan, the chief medical officer, was summoned to Peking Union Medical College Hospital, where the head of the clinical trial department told him that the trial investigators would be conducting an autopsy to see if the patients had died of the disease — they were all very sick by the time they enrolled — or of interstitial lung disease, a deadly side effect tied to the TKI class that’s been reported in Japan.

No­var­tis' sec­ond at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

Novartis’ hopes of turning one of the most surprising trial data points of the last decade into a lung cancer drug has taken another setback.

The Swiss pharma announced Monday that its IL-1 inhibitor canakinumab did not significantly extend the lives or slow the disease progression of patients with previously untreated locally advanced or metastatic non-small cell lung cancer when compared to standard of-care alone.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

After flopping a test in Covid-19 earlier this year, Angion’s lead organ damage drug has now hit the skids again in kidney transplant patients.

Angion and partner Vifor Pharma’s ANG-3777 failed to beat out placebo in terms of improving eGFR, a measure of kidney function, in patients who had received a deceased donor kidney transplant and were at high risk of developing what is known as delayed graft function, according to Phase III results released Tuesday.

(Photo courtesy Pfizer)

FDA's vac­cine ad­comm votes al­most unan­i­mous­ly in fa­vor of Pfiz­er's Covid-19 vac­cine for younger chil­dren

The FDA’s Vaccines and Related Biological Products Advisory Committee on Tuesday voted 17-0, with one panelist abstaining, that the benefits of the Pfizer-BioNTech Covid-19 vaccine outweigh the risks for children between the ages of five and 12.

The vote will likely trigger a process that could allow the shots to begin rolling out as early as next week.

The vaccine, which is one-third of the adult Pfizer dose, proved to be about 90% effective in a placebo-controlled trial in which about 1,500 kids in this age range received the vaccine, and only about 12% of those receiving the vaccine had any adverse event. All serious adverse events in the trial were unrelated to the vaccine.

Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)

Mod­er­na chips in fur­ther on African vac­cine sup­ply — but ad­vo­cates are call­ing for even more

In a sign of its growing commitment to the continent, Moderna will supply up to 110 million doses of its Covid-19 vaccine to the African Union, the company announced Tuesday. And CEO Stéphane Bancel said it’s just the first step.

“We believe our vaccine can play an important role in addressing the needs of low-income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and superior storage and handling conditions. We recognize that access to COVID-19 vaccines continues to be a challenge in many parts of the world and we remain committed to helping to protect as many people as possible around the globe,” Bancel said in a statement.

An image of Alzheimer's brain tissue. The red show gingipains, a protein from P. gingivalis, intermixing with neurons (yellow) and glial cells (green)

An Alzheimer's dark­horse fails its first big tri­al, but of­fers hope for a long-over­looked hy­poth­e­sis

Three years ago, Cortexyme emerged out of obscurity with some big-name backers and an unorthodox approach to treating Alzheimer’s.

They moved their drug into a pivotal study the next year, offering one of the first major tests for a hypothesis that has fluttered on the outskirts of Alzheimer’s research for decades: that, in many cases, the disease is driven by infectious agents — the havoc they wreak in the brain and the inflammation the body uses to try to fend them off. And that quashing the infection could slow patients’ cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,800+ biopharma pros reading Endpoints daily — and it's free.

Ugur Sahin, AP Images

As pres­sure to share tech­nol­o­gy mounts, BioN­Tech se­lects Rwan­da for lat­est vac­cine site

BioNTech’s first mRNA-based vaccine site in Africa will call Rwanda home, and construction is set to start in mid-2022, the company announced Tuesday at a public health forum.

The German company signed a memorandum of understanding, after a meeting between Rwanda’s Minister of Health, Daniel Ngamije, Senegal’s Minister of Foreign Affairs Aïssata Tall Sall, and senior BioNTech officials. Construction plans have been finalized, and assets have been ordered. The agreement will help bring end-to-end manufacturing to Africa, and as many as several hundred million doses of vaccines per year, though initial production will be more modest.